Last reviewed · How we verify
Low-Dose Lidocaine
Low-dose lidocaine blocks sodium channels and modulates inflammatory and neuropathic pain pathways at sub-anesthetic concentrations.
Low-dose lidocaine blocks sodium channels and modulates inflammatory and neuropathic pain pathways at sub-anesthetic concentrations. Used for Chronic pain syndromes, Neuropathic pain, Post-operative pain management.
At a glance
| Generic name | Low-Dose Lidocaine |
|---|---|
| Sponsor | The Methodist Hospital Research Institute |
| Drug class | Local anesthetic / sodium channel blocker |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that at therapeutic doses inhibits voltage-gated sodium channels, reducing neuronal excitability and pain signal transmission. At low systemic doses, it also exhibits anti-inflammatory and immunomodulatory effects, potentially reducing cytokine production and central sensitization. This makes it useful for chronic pain conditions where both neuropathic and inflammatory components are present.
Approved indications
- Chronic pain syndromes
- Neuropathic pain
- Post-operative pain management
Common side effects
- Dizziness
- Lightheadedness
- Tremor
- Perioral numbness
- Tinnitus
Key clinical trials
- Knee Injections for Obese Patients With Knee Arthritis (PHASE4)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis (PHASE4)
- Comparison of Prolotherapy and Rehabilitation Treatments in Low Back Pain (CPRTLBP) (NA)
- Low-Thoracic Epidural Anesthesia For Laparoscopic Nephrectomy. (NA)
- COMPARISON OF OPIOID-FREE AND OPIOID-BASED ANESTHESIA TECHNIQUES ON qNOX INDEX IN ABDOMINAL SURGERY UNDER GENERAL ANESTHESIA (NA)
- Regional Anesthesia in Ambulatory Endovenous Ablation Surgery (NA)
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-Dose Lidocaine CI brief — competitive landscape report
- Low-Dose Lidocaine updates RSS · CI watch RSS
- The Methodist Hospital Research Institute portfolio CI